{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:35:39Z","timestamp":1790670939065,"version":"4.1.0"},"reference-count":43,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Amarin Pharma Inc., Bedminster, New Jersey."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Despite reducing progression and promoting regression of coronary atherosclerosis, statin therapy does not fully address residual cardiovascular (CV) risk. High\u2010purity eicosapentaenoic acid (EPA) added to a statin has been shown to reduce CV events and induce regression of coronary atherosclerosis in imaging studies; however, data are from Japanese populations without high triglyceride (TG) levels and baseline EPA serum levels greater than those in North American populations. Icosapent ethyl is a high\u2010purity prescription EPA ethyl ester approved at 4\u2009g\/d as an adjunct to diet to reduce TG levels in adults with TG levels &gt;499\u2009mg\/dL. The objective of the randomized, double\u2010blind, placebo\u2010controlled EVAPORATE study is to evaluate the effects of icosapent ethyl 4\u2009g\/d on atherosclerotic plaque in a North American population of statin\u2010treated patients with coronary atherosclerosis, TG levels of 200 to 499\u2009mg\/dL, and low\u2010density lipoprotein cholesterol levels of 40 to 115\u2009mg\/dL. The primary endpoint is change in low\u2010attenuation plaque volume measured by multidetector computed tomography angiography. Secondary endpoints include incident plaque rates; quantitative changes in different plaque types and morphology; changes in markers of inflammation, lipids, and lipoproteins; and the relationship between these changes and plaque burden and\/or plaque vulnerability. Approximately 80 patients will be followed for 9 to 18\u2009months. The clinical implications of icosapent ethyl 4\u2009g\/d treatment added to statin therapy on CV endpoints are being evaluated in the large CV outcomes study REDUCE\u2010IT. EVAPORATE will provide important imaging\u2010derived data that may add relevance to the clinically derived outcomes from REDUCE\u2010IT.<\/jats:p>","DOI":"10.1002\/clc.22856","type":"journal-article","created":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T22:19:58Z","timestamp":1516832398000},"page":"13-19","source":"Crossref","is-referenced-by-count":68,"title":["Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200\u2013499 mg\/dL) on statin therapy: Rationale and design of the EVAPORATE study"],"prefix":"10.1002","volume":"41","author":[{"given":"Matthew","family":"Budoff","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Los Angeles Biomedical Research Institute  Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Brent Muhlestein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Intermountain Heart Institute Intermountain Medical Center  Murray Utah"},{"name":"Department of Internal Medicine University of Utah  Salt Lake City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6659-5332","authenticated-orcid":false,"given":"Viet T.","family":"Le","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Intermountain Heart Institute Intermountain Medical Center  Murray Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi T.","family":"May","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Intermountain Heart Institute Intermountain Medical Center  Murray Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sion","family":"Roy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Los Angeles Biomedical Research Institute  Torrance, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Cardiology California Cardiovascular Institute  Fresno, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-13-26"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.07.035"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S104369"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.10.011"},{"key":"e_1_2_6_6_1","article-title":"Eicosapentaenoic acid\u2013enriched high\u2010density lipoproteins exhibit anti\u2010atherogenic properties","author":"Tanaka N","year":"2017","journal-title":"Circ J."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.04.015"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.05.031"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2017.02.004"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"e_1_2_6_11_1","unstructured":"Vascepa [package insert]. Bedminster NJ: Amarin Pharma Inc.; 2017."},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prostaglandins.2016.07.007"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-012-0002-3"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.08.005"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.02.008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.rli.0000254408.96355.85"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22646"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3945\/jn.114.202424"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.11.004"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.08.019"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-15-0813"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.6551"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2017.07.007"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(92)91222-P"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.18002"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1788"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-12-55"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.ijcard.2016.07.079","article-title":"Association of CD34\/CD133\/VEGFR2\u2010positive cell numbers with eicosapentaenoic acid and postprandial hyperglycemia in patients with coronary artery disease","volume":"221","author":"Morishita T","year":"2016","journal-title":"Int J Cardiol."},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(12)61732-X","article-title":"The impact of a pure\u2010EPA omega\u20103 fatty acid on coronary plaque stabilization: a plaque component analysis with 64\u2010slice multi\u2010detector row computed tomography [abstract]","volume":"59","author":"Shintani Y","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"e_1_2_6_30_1","first-page":"1052","article-title":"The impact of eicosapentaenoic acid on prevention of plaque progression detected by coronary computed tomography angiography [abstract P5235]","volume":"37","author":"Nagahara Y","year":"2016","journal-title":"Eur Heart J."},{"key":"e_1_2_6_31_1","article-title":"Omega\u20103 fatty acid added to statin prevents progression of fibrous coronary artery plaque compared to statin alone in patients with coronary artery disease [abstract]","volume":"134","author":"Alfaddagh A","year":"2016","journal-title":"Circulation"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.01.041"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr465"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.21043"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ijcard.2011.02.056","article-title":"Assessment of progression of coronary atherosclerosis using multidetector computed tomography angiography (MDCT)","volume":"149","author":"Hamirani YS","year":"2011","journal-title":"Int J Cardiol."},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.058"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1476-7120-10-33","article-title":"Comparison between integrated backscatter intravascular ultrasound and 64\u2010slice multi\u2010detector row computed tomography for tissue characterization and volumetric assessment of coronary plaques","volume":"10","author":"Yamaki T","year":"2012","journal-title":"Cardiovasc Ultrasound."},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jjcc.2011.11.010","article-title":"Non\u2010obstructive low attenuation coronary plaque predicts three\u2010year acute coronary syndrome events in patients with hypertension: multidetector computed tomographic study","volume":"59","author":"Nakanishi K","year":"2012","journal-title":"J Cardiol."},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.22692"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.04.008"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300955"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.038"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001282"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.023"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fclc.22856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.22856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T23:54:38Z","timestamp":1695772478000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.22856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.1002\/clc.22856"],"URL":"https:\/\/doi.org\/10.1002\/clc.22856","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}